‘Monday morning quarterbacks’ question EMA rigor, says unreimbursed CEO
This article was originally published in Scrip
Executive Summary
Jame Bianco, Cell Therapeutics' CEO, says there is a "fundamental issue" with the European Medicines Agency's drug approval process and the subsequent wrangling with Europe's pricing and reimbursement bodies, he said. His comments come after Pixuvri (pixantrone) was rejected by NICE, England's health technology appraisal institute (scripintelligence.com, 11 April 2013).